Aim Immunotech INC Form 4 insider transactions

Director Stewart Appelrouth acquired 8,768 shares of AIM ImmunoTech Inc. common stock on December 31, 2024, in lieu of cash compensation under the company's Cash Conservation Plan.

Nancy Bryan, a director at AIM ImmunoTech Inc., acquired 26,305 shares of common stock on December 31, 2024, in lieu of cash compensation under the company's Cash Conservation Plan.

Director William M Mitchell acquired 26,305 shares of AIM ImmunoTech Inc. common stock on December 31, 2024, in lieu of cash compensation under the company's Cash Conservation Plan.

Director William M. Mitchell sold 4,580 shares of AIM ImmunoTech Inc. on December 19, 2024.

AIM ImmunoTech's CEO, Thomas K. Equels, purchased 22,727 shares of common stock at $0.206 per share on December 18, 2024.

AIM ImmunoTech director William M Mitchell acquired 24,452 shares of common stock as compensation under the company's Cash Conservation Plan.

Director Stewart Appelrouth acquired 24,452 shares of AIM ImmunoTech Inc. common stock on December 13, 2024, as part of the company's Cash Conservation Plan.

Director Nancy Bryan acquired 24,452 shares of AIM ImmunoTech stock in lieu of cash compensation under the company's Cash Conservation Plan.

A director of AIM ImmunoTech Inc. unintentionally acquired shares of common stock in a recent transaction.

AIM ImmunoTech director William M Mitchell acquired 22,645 shares of common stock as part of a compensation plan.

Director Stewart Appelrouth acquired 22,645 shares of AIM ImmunoTech stock as part of a compensation plan.

Director Nancy Bryan acquired 22,645 shares of AIM ImmunoTech stock as part of a compensation plan.

AIM ImmunoTech's CEO, Thomas K. Equels, purchased 85,000 shares of common stock at $0.199 per share on November 20, 2024.

Director Stewart Appelrouth purchased 81,953 shares of AIM ImmunoTech Inc. at a price of $0.193 per share on November 20, 2024.

AIM ImmunoTech's CEO, Thomas K Equels, purchased 60,110 shares of common stock at $0.183 per share on November 20, 2024.

AIM ImmunoTech's CEO, Thomas K Equels, recently purchased 5,000 shares of the company's common stock at a price of $0.303 per share.

AIM ImmunoTech's CEO and President, Thomas K Equels, acquired 20,000 shares of common stock at $0.308 per share on September 13, 2024.

Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., acquired 312,500 shares of common stock at a price of $0.32 per share on September 11, 2024.

Peter W. Rodino III, COO, Secretary, and General Counsel of AIM ImmunoTech Inc., reports acquiring shares of common stock in a transaction dated August 12, 2024.

Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., reports acquiring 377,358 shares of common stock at $0.265 per share and disposing of 1,155,542 shares on August 12, 2024.

CEO Thomas Equels of AIM ImmunoTech Inc. recently purchased 61,729 shares of common stock at $0.405 per share, increasing his direct holdings in the company.

Peter W. Rodino III, COO, Secretary, and General Counsel of AIM ImmunoTech Inc., acquired 30,865 shares of common stock at $0.405 per share on May 6, 2024.

Peter W. Rodino III, COO, Secretary, and General Counsel of AIM ImmunoTech Inc., reports acquisition of options.

CEO and President Thomas K Equels reports acquiring 300,000 options of AIM ImmunoTech Inc. on November 30, 2023.

Director Nancy Bryan purchased 38,462 shares of AIM ImmunoTech Inc. at $0.39 per share on March 21, 2024.

Director Stewart Appelrouth reports acquiring and disposing of AIM ImmunoTech Inc. shares on March 15, 2024.

AIM ImmunoTech's CEO and President, Thomas K Equels, purchased 75,758 shares of common stock at $0.33 per share on March 15, 2024.

Peter Rodino III, COO, Secretary, and General Counsel of AIM ImmunoTech Inc., purchased 37,879 shares of common stock at $0.33 per share on March 15, 2024.